Orchestra Total Operating Expenses vs Ebitda Analysis
| OBIO Stock | 5.26 0.08 1.50% |
Orchestra BioMed financial indicator trend analysis is much more than just breaking down Orchestra BioMed Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Orchestra BioMed Holdings is a good investment. Please check the relationship between Orchestra BioMed Total Operating Expenses and its Ebitda accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Total Operating Expenses vs Ebitda
Total Operating Expenses vs Ebitda Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Orchestra BioMed Holdings Total Operating Expenses account and Ebitda. At this time, the significance of the direction appears to have pay attention.
The correlation between Orchestra BioMed's Total Operating Expenses and Ebitda is -0.92. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Ebitda in the same time period over historical financial statements of Orchestra BioMed Holdings, assuming nothing else is changed. The correlation between historical values of Orchestra BioMed's Total Operating Expenses and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Orchestra BioMed Holdings are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Total Operating Expenses i.e., Orchestra BioMed's Total Operating Expenses and Ebitda go up and down completely randomly.
Correlation Coefficient | -0.92 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Ebitda
Most indicators from Orchestra BioMed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Orchestra BioMed Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. As of the 13th of December 2024, Selling General Administrative is likely to drop to about 14.6 M. Issuance Of Capital Stock is expected to grow at the current pace this year
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 181K | 287K | 227.4K | Interest Income | 50K | 3.8M | 4.0M |
Orchestra BioMed fundamental ratios Correlations
Click cells to compare fundamentals
Orchestra BioMed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Orchestra BioMed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.Moving against Orchestra Stock
| 0.6 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.43 | LLY | Eli Lilly | PairCorr |
| 0.34 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.
The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.